Form 8-K - Current report:
SEC Accession No. 0001104659-25-060902
Filing Date
2025-06-20
Accepted
2025-06-20 08:00:54
Documents
17
Period of Report
2025-06-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2518285d1_8k.htm   iXBRL 8-K 43898
2 EXHIBIT 4.1 tm2518285d1_ex4-1.htm EX-4.1 87719
3 EXHIBIT 4.2 tm2518285d1_ex4-2.htm EX-4.2 86716
4 EXHIBIT 4.3 tm2518285d1_ex4-3.htm EX-4.3 90115
5 EXHIBIT 10.1 tm2518285d1_ex10-1.htm EX-10.1 70677
6 EXHIBIT 99.1 tm2518285d1_ex99-1.htm EX-99.1 13547
  Complete submission text file 0001104659-25-060902.txt   660457

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA acxp-20250617.xsd EX-101.SCH 3023
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE acxp-20250617_lab.xml EX-101.LAB 34239
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acxp-20250617_pre.xml EX-101.PRE 22364
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2518285d1_8k_htm.xml XML 3685
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40536 | Film No.: 251059123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)